Bronnen:
- Montalban X, et al. Primary analysis of a randomised, placebo-controlled, phase 2 study of the Bruton's tyrosine kinase inhibitor evobrutinib (M2951) in patients with relapsing multiple sclerosis. ECTRIMS 2018, abstract 322.
Bronnen:
jan 2024 | Neuro-vasculair
dec 2023 | Bewegingsstoornissen